FDA Approval: On-X aortic valves with less warfarin

U.S. FDA Grants Expanded Labeling Claim to On-X Life Technologies, Reducing Blood-Thinning Requirements for Heart Valve Patients Thousands With On-X Aortic Implant May Be Able to Reduce Medication Regimen AUSTIN, TX — April 2, 2015 — Thousands of Americans with On-X® Aortic Heart Valves may be able to reduce their regular blood-thinning medication regimen, thanks to […]

On-X LTI to present its newest advance in heart valve technology at AATS

On-X Life Technologies to present its newest advance in heart valve technology at “94th Annual Scientific Meeting” of the American Association for Thoracic Surgery (AATS) in Toronto AUSTIN, TX — April 24, 2014 — Privately held On-X® Life Technologies, Inc. (On-X LTI) announced today that it will present the results of the PROACT1 clinical trial […]

50-year retrospective study

50-year retrospective study shows On-X Life Technologies’ mechanical heart valves have “the lowest incidence of valve thrombosis” Data presented at 22nd Annual Meeting of the Asian Society for Cardiovascular and Thoracic Surgery (ASCVTS) AUSTIN, TX — April 4, 2014 — Privately held On-X® Life Technologies Inc., whose mechanical heart valves have been implanted in more […]

On-X LTI to present its newest advance in heart valve technology

On-X Life Technologies to present its newest advance in heart valve technology at the Asian Society for Cardiovascular and Thoracic Surgery (ASCVTS) in Istanbul, Turkey “We are excited about introducing the On-X® Plus 1.5™ Aortic Heart Valve to this important surgical society. This valve represents a new paradigm by which clinicians can manage their patients […]

On-X LTI begins shipping On-X Plus 1.5 Aortic Heart Valves

On-X Life Technologies begins shipping its On-X® Plus 1.5™ Aortic Heart Valve to European hospitals “While the On-X® Plus 1.5™ Aortic Heart Valve allows European clinicians for the first time to manage their patients on a reduced dose of warfarin. Our launch of this important new heart valve builds upon our 18 years of service […]

OnXLTI prepares to sell On-X Plus 1.5 Aortic Heart Valve

On-X LTI prepares European sales force to sell On-X® Plus 1.5™ Aortic Heart Valve “While the On-X® Plus 1.5™ Aortic Heart Valve represents a new paradigm by which clinicians can manage their patients on a reduced dose of warfarin, we are proud to note that On-X has been successfully selling mechanical valves in Europe since […]

On-X Life Technologies to launch its On-X Plus 1.5 Aortic Heart Valve

On-X Life Technologies to launch its On-X® Plus 1.5™ Aortic Heart Valve at Annual Meeting of the Society for Cardiothoracic Surgery (SCS) in Great Britain & Ireland “The On-X® Plus 1.5™ Aortic Heart Valve allows clinicians to maintain patients on a lower dose of blood thinner, which has been shown to result in greater than […]

On-X Life Technologies reports CE mark approval

On-X Life Technologies reports CE mark approval to sell its mechanical aortic heart valve with an expanded labeling claim: a reduction in the required use of blood thinners “This approval allows European clinicians to maintain patients on a lower dose of anticoagulant, which has been shown in a multicenter clinical trial (PROACT: Prospective On-X Anticoagulation […]

On-X Heart Valve Study Results

Presented at the Society for Heart Valve Disease 7th Biennial Congress Two PROACT Abstracts Present Data Showing Patients on Low Anticoagulation Therapy Do Well with the On-X® Prosthetic Heart Valve AUSTIN, TX — June 25, 2013 — On-X® Life Technologies, Inc. (On-X LTI) announced today that two new PROACT abstracts further demonstrating the safety of […]

ISPOR Meeting Presentation

Economic Model of the Life-time Cost Impact of Heart Valve Prosthetic Choice Life-time costs savings of choosing an On-X® Prosthetic Heart Valve with no risk of re-operation compared to a stented tissue valve replaced with a transcatheter valve is estimated at $376,000 AUSTIN, TX — May 21, 2013 — On-X® Life Technologies, Inc. (On-X LTI) […]

Onxlti Responsive Menu
Menu